Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults
@article{McDonnell2006SingleDoseR6, title={Single‐Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults}, author={A. McDonnell and K. L. Lenz and D. Frei‐Lahr and J. Hayslip and P. Hall}, journal={Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy}, year={2006}, volume={26} }
Rasburicase is currently approved at a dosage of 0.15–0.2 mg/kg once/day for 5 days in pediatric patients with cancer to lower plasma uric acid concentrations and manage tumor lysis syndrome (TLS). Information on rasburicase dosing in adults is limited, with some data on using rasburicase as a single dose instead of multiple daily doses. Therefore, we evaluated the efficacy of a single dose of rasburicase for preventing or managing TLS in adults. We collected retrospective data for 11 adults… CONTINUE READING
Topics from this paper
64 Citations
Efficacy of Single Low-Dose Rasburicase in Management of Tumor Lysis Syndrome in Leukemia and Lymphoma Patients.
- Medicine
- Clinical lymphoma, myeloma & leukemia
- 2020
Single 6-mg dose of rasburicase: The experience in a large academic medical center
- Medicine
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- 2018
- 3
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
- Medicine
- Annals of oncology : official journal of the European Society for Medical Oncology
- 2012
- 64
Reduced administration of rasburicase for tumor lysis syndrome: A single-institution experience.
- Medicine
- Oncology letters
- 2015
- 3
- PDF
Oncology: Fixed-Dose Rasburicase 6 mg for Hyperuricemia and Tumor Lysis Syndrome in High-Risk Cancer Patients
- Medicine
- The Annals of pharmacotherapy
- 2010
- 35
Fixed, low-dose rasburicase for the treatment or prevention of hyperuricemia in adult oncology patients
- Medicine
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- 2015
- 19
A single, fixed dose of rasburicase (6 mg maximum) for treatment of tumor lysis syndrome in adults
- Medicine
- European journal of haematology
- 2010
- 28
Evaluation of a low, weight-based dose of rasburicase in adult patients for the treatment or prophylaxis of tumor lysis syndrome
- Medicine
- Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
- 2011
- 30
Rasburicase and tumor lysis syndrome: lower dosage, consideration of indications, and hyperhydration.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2011
- 17
References
SHOWING 1-10 OF 15 REFERENCES
Treatment of Impending Tumor Lysis with Single-Dose Rasburicase
- Medicine
- The Annals of pharmacotherapy
- 2003
- 55
- Highly Influential
A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy.
- Medicine
- Leukemia research
- 2005
- 52
Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2001
- 300
Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 (Groupe d'Etude des Lymphomes de l'Adulte Trial on Rasburicase Activity in Adult Lymphoma) study.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2003
- 186
Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome.
- Medicine
- The American journal of medicine
- 2004
- 280
Successful treatment of hyperuricemia with low doses of recombinant urate oxidase in four patients with hematologic malignancy and tumor lysis syndrome
- Biology, Medicine
- Leukemia
- 2003
- 24
- Highly Influential
- PDF